Synthetic Biologics, Inc. (AMEX:SYN) with the stream of 7.72% in the last hour of trading session.
Synthetic Biologics, Inc. (SYN) had a good day on the market for Friday January 22 as shares jumped 7.72% to close at $0.91. About 22,566,164 million shares traded hands on 10.83M trades for the day, compared with an average daily volume of 10.83M shares out of a total float of 17.95M. After opening the trading day at $0.87, shares of Synthetic Biologics, Inc. stayed within a range of $0.85 to $0.95.
With today’s gains, Synthetic Biologics, Inc. now has a market cap of $45.38M. Shares of Synthetic Biologics, Inc. have been trading within a range of $0.25 and $1.70 over the last year, and it had a 50-day SMA of $94.73% and a 200-day SMA of $103.89%.
The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 22,566,164 shares.
Synthetic Biologics, Inc. has P/S value of 0 while its P/B esteem remains at 0. Likewise, the company has Return on Assets of -109.60%, Return on Equity of 207.90% and Return on Investment of 0. The company demonstrates Gross Margin and Operating Margin of 0 and 0 respectively.
SYN’s price to sales ratio for trailing twelve months was 0 and price to book ratio for most recent quarter was 0, whereas price to cash per share for the most recent quarter was 7.56. The Company’s price to free cash flow for trailing twelve months was recorded as 0.
Historical Performances to Consider:
The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:
On a Monthly basis the stock was 171.88%. On a weekly basis, the stock remained 20.25%. The half-yearly performance for the stock has 70.33%, while the quarterly performance was 183.37%. Looking further out we can see that the stock has moved 138.02% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 65.77.
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.